Insider Transactions in Q1 2022 at Aprea Therapeutics, Inc. (APRE)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2022
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,700
+36.11%
|
-
|
|
Mar 10
2022
|
Eyal C. Attar SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+32.3%
|
-
|
|
Mar 10
2022
|
Scott M Coiante SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+26.41%
|
-
|
|
Mar 10
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,989
-6.25%
|
$1,989
$1.82 P/Share
|
|
Mar 10
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.44%
|
-
|
|
Mar 10
2022
|
Christian S Schade Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,100
+28.18%
|
-
|
|
Feb 28
2022
|
Eyal C. Attar SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
36,000
-43.37%
|
$36,000
$1.73 P/Share
|
|
Feb 25
2022
|
Scott M Coiante SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,817
-16.2%
|
$14,817
$1.74 P/Share
|
|
Feb 25
2022
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,326
-7.72%
|
$1,326
$1.74 P/Share
|
|
Feb 25
2022
|
Christian S Schade Director |
SELL
Payment of exercise price or tax liability
|
Direct |
21,644
-12.25%
|
$21,644
$1.74 P/Share
|